|Videos|November 21, 2015

Yale Cancer Center Merges Cutting Edge Research with Personalized Medicine

Episodes in this series

Now Playing

EP. 1 Yale Cancer Center Merges Cutting Edge Research with Personalized Medicine

Roy H. Decker, MD, PhD, discusses the use of pembrolizumab with concurrent chemoradiotherapy in patients with inoperable, locally advanced non–small cell lung cancer.

EP. 2 Dr. Decker on Pembrolizumab With Concurrent Chemoradiotherapy in Inoperable Locally Advanced NSCLC

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C)

EP. 3 Dr. Anees Chagpar Named 2021 ASCO Fellow

EP. 4 Yale Cancer Center’s Dr. Lieping Chen Elected to Prestigious National Academy of Sciences

EP. 5 Yale Research to be Presented at 2021 ASCO Annual Meeting

Jan Philipp Bewersdorf, MD, of Yale University School of Medicine

EP. 6 Dr. Bewersdorf on the Role of Allogeneic Transplant in Myelofibrosis

EP. 7 Barbara Burtness Named Interim Associate Director for Diversity, Equity, and Inclusion at Yale Cancer Center

Joseph W. Kim, MD, of Yale Cancer Center

EP. 8 Joseph W. Kim Receives Prestigious 2021 Cancer Clinical Investigator Team Leadership Award

EP. 9 Yale Cancer Center Perspective Highlights New Advances for NSCLC

EP. 10 Yale Cancer Center Study Shows Stem-Like T Cells Could Aid Immunotherapy in Cancer Treatment

Andrea L. Silber, MD, of Yale Cancer Center

EP. 11 Dr. Silber on the Importance of Improving Clinical Trial Inclusivity in Breast Cancer

EP. 12 Dr. Lustberg Discusses Ongoing Research in Breast Cancer

EP. 13 Margaret Gilshannon named Deputy Director for Finance & Administration at Yale Cancer Center

EP. 14 Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs

Eric P. Winer, MD, of Yale Cancer Center

EP. 15 Eric P. Winer to lead Yale Cancer Center and Smilow Cancer Hospital

EP. 16 Dr. Parker Discusses the Importance of Optimizing Treatment in Multiple Myeloma

EP. 17 Yale Cancer Center Study Shows New Strategy to Boost Immune System to Fight Melanoma

EP. 18 Dr. Fernandez on the Need to Refine Immunohistochemistry Testing in HER2+ Breast Cancer

EP. 19 Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

Roy S. Herbst, MD, PhD, of Yale Cancer Center

EP. 20 Immunotherapy Advances Drive Progress in Lung Cancer Treatment

Ian E. Krop, MD, PhD, of Yale Cancer Center

EP. 21 Ian E. Krop, MD, PhD, Named Chief Clinical Research Officer, Associate Cancer Center Director for Clinical Research at Yale Cancer Center

Natalia Neparidze, MD, of Yale Cancer Center

EP. 22 Yale Cancer Center Study Reveals Disparities in Telemedicine Use in Patients with Hematologic Cancers

EP. 23 Addition of Bevacizumab to Ixabepilone Is Effective, Tolerable in Platinum-Resistant Ovarian Cancer

EP. 24 Dr. Petrylak on the Rationale of the EV-103 Trial in MIBC

EP. 25 Yale Cancer Center and School of Public Health Receive Grant to Study Lifestyle Intervention in Women with Ovarian Cancer

Aarti Bhatia, MD, associate professor of medicine at Yale School of Medicine and medical oncologist at Smilow Cancer Hospital at Yale, New Haven, Connecticut.

EP. 26 Berzosertib Plus Standard Chemoradiation Elicits Promising Responses in Locally Advanced HNSCC

Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Chief Translational Research Officer, Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center.

EP. 27 Barbara Burtness Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital

EP. 28 Expert Insights on First-line Treatment Strategies in SCLC

EP. 29 Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC

EP. 30 ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC

EP. 31 Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%

EP. 32 Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC

EP. 33 Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy

EP. 34 Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond

EP. 35 LAGOON and IMFORTE Trials: Data Updates and Expert Insights

EP. 36 2L Dosing Considerations and Management Strategies for SCLC

EP. 37 Novel Treatment Approaches for SCLC and Future Perspectives

Stay up to date on the most recent and practice-changing oncology data

Latest CME

In-Person + Virtual Event

10th Annual Live Medical Crossfire®: Hematologic Malignancies

July 11-12, 2026

Virtual Event

Iowa Oncology Society

2 Sessions are Available!

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Seth A. Wander, MD, PhD; Ruta D. Rao, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Marla D. Lipsyc-Sharf, MD; Richard Zelkowitz, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Seth A. Wander, MD, PhD; Kate Baxstrom, MD

Virtual Event

Wyoming State Oncology Society

2 Sessions are Available!

Virtual Event

Kansas Society of Clinical Oncology

1 Session is Available!

Virtual Event

North Carolina Oncology Association

2 Sessions are Available!

Video

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Seth A. Wander, MD, PhD; Yang Liu, MD

Virtual Event

Louisiana Oncology Society

2 Sessions are Available!

Virtual Event

Missouri Oncology Society

2 Sessions are Available!

Virtual Event

New Mexico Society of Clinical Oncology

2 Sessions are Available!

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Virtual Event

Wisconsin Association of Hematology and Oncology

1 Session is Available!

Virtual Event

Indiana Oncology Society

2 Sessions are Available!

Virtual Event

Kentucky Society of Clinical Oncology

2 Sessions are Available!

Virtual Event

Rhode Island Oncology Society

3 Sessions are Available!

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Audio

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Video

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Audio

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Audio

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Video

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Multimedia

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Yana G. Najjar, MD; Sapna Patel, MD

Video

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Video

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Multimedia

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Multimedia

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

Multimedia

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Jacob Sands, MD; Anne Chiang, MD, PhD

Yale Cancer Center Merges Cutting Edge Research with Personalized Medicine

Episodes in this series

EP. 1 Yale Cancer Center Merges Cutting Edge Research with Personalized Medicine

EP. 2 Dr. Decker on Pembrolizumab With Concurrent Chemoradiotherapy in Inoperable Locally Advanced NSCLC

EP. 3 Dr. Anees Chagpar Named 2021 ASCO Fellow

EP. 4 Yale Cancer Center’s Dr. Lieping Chen Elected to Prestigious National Academy of Sciences

EP. 5 Yale Research to be Presented at 2021 ASCO Annual Meeting

EP. 6 Dr. Bewersdorf on the Role of Allogeneic Transplant in Myelofibrosis

EP. 7 Barbara Burtness Named Interim Associate Director for Diversity, Equity, and Inclusion at Yale Cancer Center

EP. 8 Joseph W. Kim Receives Prestigious 2021 Cancer Clinical Investigator Team Leadership Award

EP. 9 Yale Cancer Center Perspective Highlights New Advances for NSCLC

EP. 10 Yale Cancer Center Study Shows Stem-Like T Cells Could Aid Immunotherapy in Cancer Treatment

EP. 11 Dr. Silber on the Importance of Improving Clinical Trial Inclusivity in Breast Cancer

EP. 12 Dr. Lustberg Discusses Ongoing Research in Breast Cancer

EP. 13 Margaret Gilshannon named Deputy Director for Finance & Administration at Yale Cancer Center

EP. 14 Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs

EP. 15 Eric P. Winer to lead Yale Cancer Center and Smilow Cancer Hospital

EP. 16 Dr. Parker Discusses the Importance of Optimizing Treatment in Multiple Myeloma

EP. 17 Yale Cancer Center Study Shows New Strategy to Boost Immune System to Fight Melanoma

EP. 18 Dr. Fernandez on the Need to Refine Immunohistochemistry Testing in HER2+ Breast Cancer

EP. 19 Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

EP. 20 Immunotherapy Advances Drive Progress in Lung Cancer Treatment

EP. 21 Ian E. Krop, MD, PhD, Named Chief Clinical Research Officer, Associate Cancer Center Director for Clinical Research at Yale Cancer Center

EP. 22 Yale Cancer Center Study Reveals Disparities in Telemedicine Use in Patients with Hematologic Cancers

EP. 23 Addition of Bevacizumab to Ixabepilone Is Effective, Tolerable in Platinum-Resistant Ovarian Cancer

EP. 24 Dr. Petrylak on the Rationale of the EV-103 Trial in MIBC

EP. 25 Yale Cancer Center and School of Public Health Receive Grant to Study Lifestyle Intervention in Women with Ovarian Cancer

EP. 26 Berzosertib Plus Standard Chemoradiation Elicits Promising Responses in Locally Advanced HNSCC

EP. 27 Barbara Burtness Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital

EP. 28 Expert Insights on First-line Treatment Strategies in SCLC

EP. 29 Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC

EP. 30 ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC

EP. 31 Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%

EP. 32 Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC

EP. 33 Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy

EP. 34 Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond

EP. 35 LAGOON and IMFORTE Trials: Data Updates and Expert Insights

EP. 36 2L Dosing Considerations and Management Strategies for SCLC

EP. 37 Novel Treatment Approaches for SCLC and Future Perspectives

Related Content

First-Line Pemigatinib Drives PFS Benefit in FGFR2-Rearranged Cholangiocarcinoma

Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLC

ctDNA-Guided Adjuvant Chemotherapy Significantly Improves DFS, TTR in Stage II Colon Cancer

BREAKWATER Cohort 3 Data Support FOLFIRI as a Chemo Backbone With Encorafenib/Cetuximab in BRAF V600E+ mCRC

Adjuvant Selpercatinib Significantly Improves EFS in Early-Stage RET Fusion–Positive NSCLC

Latest CME

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Iowa Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Wyoming State Oncology Society

Kansas Society of Clinical Oncology

North Carolina Oncology Association

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Louisiana Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Wisconsin Association of Hematology and Oncology

Indiana Oncology Society

Kentucky Society of Clinical Oncology

Rhode Island Oncology Society

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breaking Down the Rationale for Targeting TROP2 in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC